120 related articles for article (PubMed ID: 34041490)
1. Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted blood-brain barrier permeability.
Borsari C; Keles E; Treyer A; De Pascale M; Hebeisen P; Hamburger M; Wymann MP
RSC Med Chem; 2021 Jan; 12(4):579-583. PubMed ID: 34041490
[TBL] [Abstract][Full Text] [Related]
2. A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor.
Borsari C; Rageot D; Dall'Asen A; Bohnacker T; Melone A; Sele AM; Jackson E; Langlois JB; Beaufils F; Hebeisen P; Fabbro D; Hillmann P; Wymann MP
J Med Chem; 2019 Sep; 62(18):8609-8630. PubMed ID: 31465220
[TBL] [Abstract][Full Text] [Related]
3. Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood-brain barrier penetration models.
Hellinger E; Veszelka S; Tóth AE; Walter F; Kittel A; Bakk ML; Tihanyi K; Háda V; Nakagawa S; Duy TD; Niwa M; Deli MA; Vastag M
Eur J Pharm Biopharm; 2012 Oct; 82(2):340-51. PubMed ID: 22906709
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of blood-brain barrier and blood-cerebrospinal fluid barrier permeability of 2-phenoxy-indan-1-one derivatives using in vitro cell models.
Hu HH; Bian YC; Liu Y; Sheng R; Jiang HD; Yu LS; Hu YZ; Zeng S
Int J Pharm; 2014 Jan; 460(1-2):101-7. PubMed ID: 24262988
[TBL] [Abstract][Full Text] [Related]
5. Comparison of blood-brain barrier permeability assays: in situ brain perfusion, MDR1-MDCKII and PAMPA-BBB.
Di L; Kerns EH; Bezar IF; Petusky SL; Huang Y
J Pharm Sci; 2009 Jun; 98(6):1980-91. PubMed ID: 18837012
[TBL] [Abstract][Full Text] [Related]
6. Chiral pyrrolo[2,3-d]pyrimidine and pyrimido[4,5-b]indole derivatives: structure-activity relationships of potent, highly stereoselective A1-adenosine receptor antagonists.
Müller CE; Geis U; Grahner B; Lanzner W; Eger K
J Med Chem; 1996 Jun; 39(13):2482-91. PubMed ID: 8691445
[TBL] [Abstract][Full Text] [Related]
7. Predicting Blood⁻Brain Barrier Permeability of Marine-Derived Kinase Inhibitors Using Ensemble Classifiers Reveals Potential Hits for Neurodegenerative Disorders.
Plisson F; Piggott AM
Mar Drugs; 2019 Jan; 17(2):. PubMed ID: 30699889
[TBL] [Abstract][Full Text] [Related]
8. In vitro assessment of the interactions of dopamine β-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein.
Bicker J; Alves G; Fortuna A; Soares-da-Silva P; Falcão A
Eur J Pharm Sci; 2018 May; 117():35-40. PubMed ID: 29428540
[TBL] [Abstract][Full Text] [Related]
9. [Advances in the MDCK-MDR1 cell model and its applications to screen drug permeability].
Liu Y; Zeng S
Yao Xue Xue Bao; 2008 Jun; 43(6):559-64. PubMed ID: 18822955
[TBL] [Abstract][Full Text] [Related]
10. Elucidation of Transport Mechanism of Paeoniflorin and the Influence of Ligustilide, Senkyunolide I and Senkyunolide A on Paeoniflorin Transport through Mdck-Mdr1 Cells as Blood-Brain Barrier in Vitro Model.
Hu PY; Liu D; Zheng Q; Wu Q; Tang Y; Yang M
Molecules; 2016 Mar; 21(3):300. PubMed ID: 26950101
[TBL] [Abstract][Full Text] [Related]
11. Rapamycin decreased blood-brain barrier permeability in control but not in diabetic rats in early cerebral ischemia.
Chi OZ; Kiss GK; Mellender SJ; Liu X; Weiss HR
Neurosci Lett; 2017 Jul; 654():17-22. PubMed ID: 28625574
[TBL] [Abstract][Full Text] [Related]
12. Flavonoid permeability across an in situ model of the blood-brain barrier.
Youdim KA; Qaiser MZ; Begley DJ; Rice-Evans CA; Abbott NJ
Free Radic Biol Med; 2004 Mar; 36(5):592-604. PubMed ID: 14980703
[TBL] [Abstract][Full Text] [Related]
13. Intestinal and blood-brain barrier permeability of ginkgolides and bilobalide: in vitro and in vivo approaches.
Madgula VL; Avula B; Yu YB; Wang YH; Tchantchou F; Fisher S; Luo Y; Khan IA; Khan SI
Planta Med; 2010 Apr; 76(6):599-606. PubMed ID: 19937548
[TBL] [Abstract][Full Text] [Related]
14. Validation of Human MDR1-MDCK and BCRP-MDCK Cell Lines to Improve the Prediction of Brain Penetration.
Feng B; West M; Patel NC; Wager T; Hou X; Johnson J; Tremaine L; Liras J
J Pharm Sci; 2019 Jul; 108(7):2476-2483. PubMed ID: 30794795
[TBL] [Abstract][Full Text] [Related]
15. Glutamate-Mediated Blood-Brain Barrier Opening: Implications for Neuroprotection and Drug Delivery.
Vazana U; Veksler R; Pell GS; Prager O; Fassler M; Chassidim Y; Roth Y; Shahar H; Zangen A; Raccah R; Onesti E; Ceccanti M; Colonnese C; Santoro A; Salvati M; D'Elia A; Nucciarelli V; Inghilleri M; Friedman A
J Neurosci; 2016 Jul; 36(29):7727-39. PubMed ID: 27445149
[TBL] [Abstract][Full Text] [Related]
16. Blood-brain barrier permeability and neuroprotective effects of three main alkaloids from the fruits of Euodia rutaecarpa with MDCK-pHaMDR cell monolayer and PC12 cell line.
Zhang YN; Yang YF; Yang XW
Biomed Pharmacother; 2018 Feb; 98():82-87. PubMed ID: 29245070
[TBL] [Abstract][Full Text] [Related]
17. In silico modeling on ADME properties of natural products: Classification models for blood-brain barrier permeability, its application to traditional Chinese medicine and in vitro experimental validation.
Zhang X; Liu T; Fan X; Ai N
J Mol Graph Model; 2017 Aug; 75():347-354. PubMed ID: 28628860
[TBL] [Abstract][Full Text] [Related]
18. Influence of polyunsaturated fatty acids on Cortisol transport through MDCK and MDCK-MDR1 cells as blood-brain barrier in vitro model.
Navarro C; González-Álvarez I; González-Álvarez M; Manku M; Merino V; Casabó VG; Bermejo M
Eur J Pharm Sci; 2011 Feb; 42(3):290-9. PubMed ID: 21182940
[TBL] [Abstract][Full Text] [Related]
19. Permeability changes in the blood-brain barrier: causes and consequences.
Pardridge WM; Connor JD; Crawford IL
CRC Crit Rev Toxicol; 1975 Jan; 3(2):159-99. PubMed ID: 1093805
[TBL] [Abstract][Full Text] [Related]
20. Thermolysis of benzannulated enyne-carbodiimides. Application in the synthesis of pyrido[1',2':1,2]pyrimido[4,5-b]indoles and related heteroaromatic compounds.
Lu X; Petersen JL; Wang KK
J Org Chem; 2002 Nov; 67(22):7797-801. PubMed ID: 12398505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
